$NDRA
ENDRA Life Sciences Inc.

2023 Q3 Form 10-Q Financial Statement

#000165495423010779 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.496M $1.594M $1.724M
YoY Change -5.72% -7.53% 18.48%
% of Gross Profit
Research & Development $1.633M $1.400M $1.848M
YoY Change -10.79% -24.21% 5.88%
% of Gross Profit
Depreciation & Amortization $32.06K $35.27K $21.70K
YoY Change 34.74% 62.5% -35.66%
% of Gross Profit
Operating Expenses $3.129M $2.995M $3.572M
YoY Change -8.43% -16.16% 11.61%
Operating Profit -$3.129M -$2.995M -$3.572M
YoY Change -8.43% -16.16% 11.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $28.23K $437.4K -$19.37K
YoY Change -222.66% -2357.84% -1883.98%
Pretax Income -$3.101M -$2.557M -$3.591M
YoY Change -9.87% -28.79% 12.25%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.101M -$2.557M -$3.591M
YoY Change -9.87% -28.79% 12.25%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.40 -$0.43 -$58.25K
COMMON SHARES
Basic Shares Outstanding 7.482M shares 7.482M shares 63.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.330M $4.819M $11.28M
YoY Change -58.46% -57.27% -19.69%
Cash & Equivalents $3.335M $4.819M $11.28M
Short-Term Investments
Other Short-Term Assets $310.0K $506.9K $834.9K
YoY Change -66.09% -39.28% 13846.88%
Inventory $2.758M $2.758M $2.375M
Prepaid Expenses $305.9K $506.9K $834.9K
Receivables
Other Receivables
Total Short-Term Assets $6.398M $8.084M $14.49M
YoY Change -44.68% -44.2% -11.35%
LONG-TERM ASSETS
Property, Plant & Equipment $160.8K $192.9K $239.5K
YoY Change -30.27% -19.48% 24.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $650.0K $536.1K $5.986K
YoY Change 10751.42% 8855.06%
Total Long-Term Assets $1.205M $1.161M $821.8K
YoY Change 54.86% 41.25% -8.65%
TOTAL ASSETS
Total Short-Term Assets $6.398M $8.084M $14.49M
Total Long-Term Assets $1.205M $1.161M $821.8K
Total Assets $7.603M $9.245M $15.31M
YoY Change -38.4% -39.61% -11.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $419.1K $414.9K $785.1K
YoY Change -34.17% -47.15% -2.73%
Accrued Expenses $1.720M $1.590M $717.3K
YoY Change 60.98% 121.61% -13.67%
Deferred Revenue
YoY Change
Short-Term Debt $28.48K $28.48K $0.00
YoY Change
Long-Term Debt Due $30.00K $28.48K
YoY Change
Total Short-Term Liabilities $2.169M $2.033M $1.502M
YoY Change 27.23% 35.32% -8.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $28.48K
YoY Change -100.0% -100.0% 0.0%
Other Long-Term Liabilities $240.0K $281.2K $444.2K
YoY Change -40.85% -36.7% -24.23%
Total Long-Term Liabilities $237.2K $281.2K $472.7K
YoY Change -45.39% -40.52% -23.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.169M $2.033M $1.502M
Total Long-Term Liabilities $237.2K $281.2K $472.7K
Total Liabilities $2.407M $2.314M $1.975M
YoY Change 12.49% 17.17% -12.33%
SHAREHOLDERS EQUITY
Retained Earnings -$90.47M -$87.37M -$75.14M
YoY Change 15.13% 16.28% 19.41%
Common Stock $841.00 $748.00 $6.315K
YoY Change -86.68% -88.16% 50.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.196M $6.931M $13.33M
YoY Change
Total Liabilities & Shareholders Equity $7.603M $9.245M $15.31M
YoY Change -38.4% -39.61% -11.21%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$3.101M -$2.557M -$3.591M
YoY Change -9.87% -28.79% 12.25%
Depreciation, Depletion And Amortization $32.06K $35.27K $21.70K
YoY Change 34.74% 62.5% -35.66%
Cash From Operating Activities -$2.590M -$2.269M -$3.335M
YoY Change -20.23% -31.98% 18.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$59.80K
YoY Change -100.0% -100.0% -1296.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$59.80K
YoY Change -100.0% -100.0% -1296.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.120M 4.733M 7.545M
YoY Change -37.28% 192386.22%
NET CHANGE
Cash From Operating Activities -2.590M -2.269M -3.335M
Cash From Investing Activities 0.000 0.000 -59.80K
Cash From Financing Activities 1.120M 4.733M 7.545M
Net Change In Cash -1.470M 2.464M 4.151M
YoY Change -54.93% -40.63% -248.56%
FREE CASH FLOW
Cash From Operating Activities -$2.590M -$2.269M -$3.335M
Capital Expenditures $0.00 $0.00 -$59.80K
Free Cash Flow -$2.590M -$2.269M -$3.275M
YoY Change -19.86% -30.73% 16.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Inventory Net
InventoryNet
2757633 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
2644717 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
8084006 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8024114 usd
CY2022Q4 us-gaap Assets
Assets
9274147 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
281154 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
365919 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4819459 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4889098 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
5986 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
5986 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001681682
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7481603 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3169103 shares
ndra Expected Dividend Yield
ExpectedDividendYield
0 pure
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37969
dei Entity Registrant Name
EntityRegistrantName
ENDRA LIFE SCIENCES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0579295
dei Entity Address Address Line1
EntityAddressAddressLine1
3600 Green Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 350
dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48105-1570
dei City Area Code
CityAreaCode
734
dei Local Phone Number
LocalPhoneNumber
335-0468
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NDRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7481603 shares
CY2023Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
530068 usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
502576 usd
CY2023Q2 us-gaap Assets
Assets
9244776 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7481603 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3169103 shares
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1400182 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1847560 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2791496 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3060582 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
247773 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
342039 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
429389 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
681942 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1346610 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1382094 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2713008 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2684438 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2994565 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3571693 usd
us-gaap Operating Expenses
OperatingExpenses
5933893 usd
us-gaap Operating Expenses
OperatingExpenses
6426962 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2994565 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3571693 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5933893 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6426962 usd
CY2023Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
437433 usd
CY2022Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-19374 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
434015 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-22307 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
437433 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19374 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
434015 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22307 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2557132 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3591067 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5499878 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6449269 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2557132 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3591067 usd
us-gaap Net Income Loss
NetIncomeLoss
-5499878 usd
us-gaap Net Income Loss
NetIncomeLoss
-6449269 usd
CY2023Q2 ndra Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.43
CY2022Q2 ndra Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-1.17
ndra Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-1.20
ndra Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-2.46
CY2023Q2 ndra Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
5996186 shares
CY2022Q2 ndra Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
3082209 shares
ndra Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
4582645 shares
ndra Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
2617878 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9068633 usd
CY2022Q2 ndra Common Stock Issued For Cash Net Of Funding Costs Amount
CommonStockIssuedForCashNetOfFundingCostsAmount
7545460 usd
CY2022Q2 ndra Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
311349 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3591067 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13334375 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4499037 usd
CY2023Q2 ndra Common Stock Issued For Cash Net Of Funding Costs Amount
CommonStockIssuedForCashNetOfFundingCostsAmount
4712750 usd
CY2023Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
20053 usd
CY2023Q2 ndra Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
255855 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2557132 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6930563 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10784246 usd
ndra Common Stock Issued For Cash Net Of Funding Costs Amount
CommonStockIssuedForCashNetOfFundingCostsAmount
8399512 usd
ndra Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
599886 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-6449269 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13334375 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7204504 usd
ndra Common Stock Issued For Cash Net Of Funding Costs Amount
CommonStockIssuedForCashNetOfFundingCostsAmount
4712750 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
20053 usd
ndra Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
493134 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-5499878 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6930563 usd
us-gaap Net Income Loss
NetIncomeLoss
-5499878 usd
us-gaap Net Income Loss
NetIncomeLoss
-6449269 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69781 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40739 usd
ndra Write Off Fixed Assets
WriteOffFixedAssets
0 usd
ndra Write Off Fixed Assets
WriteOffFixedAssets
599886 usd
us-gaap Share Based Compensation
ShareBasedCompensation
493134 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
73974 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
67158 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-44107 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
513140 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-112916 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1090150 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
318550 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-51072 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-73980 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-64284 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4775442 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6433852 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
149153 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-149153 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4712750 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8399512 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
20053 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4732803 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8399512 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69639 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1816507 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4889098 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9461534 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4819459 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11278041 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
ndra Stock Dividend Payable
StockDividendPayable
-3646 usd
ndra Stock Dividend Payable
StockDividendPayable
-8049 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
431842 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
576255 usd
ndra Lease Liability
LeaseLiability
444167 usd
ndra Lease Liability
LeaseLiability
586193 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1 - Nature of the Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) has developed and is continuing to develop technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (“CT”) and magnetic resonance imaging (“MRI”) technology is unavailable or impractical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA was incorporated on July 18, 2007 as a Delaware corporation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain reclassifications have been made to the 2022 consolidated financial statements in order to conform to the current period presentations. These classifications did not impact the net loss for period ended June 30, 2023.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p>
CY2023Q2 ndra Research And Development Expense1
ResearchAndDevelopmentExpense1
1400182 usd
CY2022Q2 ndra Research And Development Expense1
ResearchAndDevelopmentExpense1
1847560 usd
ndra Research And Development Expense1
ResearchAndDevelopmentExpense1
2791496 usd
ndra Research And Development Expense1
ResearchAndDevelopmentExpense1
3060582 usd
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
454203 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1322169 shares
CY2023Q2 ndra Series A Preferred Stock
SeriesAPreferredStock
141 shares
CY2023Q2 ndra Stock Payable Share
StockPayableShare
2427 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0368 pure

Files In Submission

Name View Source Status
ndra-20230630_cal.xml Edgar Link unprocessable
0001654954-23-010779-index-headers.html Edgar Link pending
0001654954-23-010779-index.html Edgar Link pending
0001654954-23-010779.txt Edgar Link pending
0001654954-23-010779-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ndra-20230630.xsd Edgar Link pending
ndra_10q.htm Edgar Link pending
ndra_ex311.htm Edgar Link pending
ndra_ex312.htm Edgar Link pending
ndra_ex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ndra-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ndra-20230630_def.xml Edgar Link unprocessable
ndra-20230630_pre.xml Edgar Link unprocessable
ndra_10q_htm.xml Edgar Link completed